|
1
|
Yoshitani SI, Tanaka T, Kohno H and
Takashima S: Chemoprevention of azoxymethane-induced rat colon
carcinogenesis by dietary capsaicin and rotenone. Int J Oncol.
19:929–939. 2001.PubMed/NCBI
|
|
2
|
Thamilselvan V, Menon M and Thamilselvan
S: Anticancer efficacy of deguelin in human prostate cancer cells
targeting glycogen synthase kinase-3 beta/beta-catenin pathway. Int
J Cancer. 129:2916–2927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matsuda H, Yoshida K, Miyagawa K, et al:
Rotenoids and flavonoids with anti-invasion of HT1080,
anti-proliferation of U937, and differentiation-inducing activity
in HL-60 from Erycibe expansa. Bioorg Med Chem.
15:1539–1546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mulcahy P, O’Doherty A, Paucard A, O’Brien
T, Kirik D and Dowd E: Development and characterisation of a novel
rat model of Parkinson’s disease induced by sequential intranigral
administration of AAV-α-synuclein and the pesticide, rotenone.
Neuroscience. 203:170–179. 2012.PubMed/NCBI
|
|
5
|
Udeani GO, Gerhauser C, Thomas CF, et al:
Cancer chemo-preventive activity mediated by deguelin, a naturally
occurring rotenoid. Cancer Res. 57:3424–3428. 1997.PubMed/NCBI
|
|
6
|
Gills JJ, Kosmeder J II, Moon RC, Lantvit
DD and Pezzuto JM: Effect of deguelin on UVB-induced skin
carcinogenesis. J Chemother. 17:297–301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan Y, Wang Y, Tan Q, Lubet RA and You M:
Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung
tumorigenesis in A/J mice. Neoplasia. 7:1053–1057. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee HY, Oh SH, Woo JK, et al:
Chemopreventive effects of deguelin, a novel Akt inhibitor, on
tobacco-induced lung tumorigenesis. J Natl Cancer Inst.
97:1695–1699. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Long JS and Ryan KM: New frontiers in
promoting tumour cell death: targeting apoptosis, necroptosis and
autophagy. Oncogene. Feb 6–2012.(Epub ahead of print).
|
|
10
|
Chun KH, Kosmeder JW II, Sun S, et al:
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt
pathway and apoptosis in premalignant human bronchial epithelial
cells. J Natl Cancer Inst. 95:291–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Wu Q, Cui GH, Chen YQ and Li R:
Deguelin blocks cells survival signal pathways and induces
apoptosis of HL-60 cells in vitro. Int J Hematol. 89:618–623. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bortul R, Tazzari PL, Billi AM, et al:
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of
leukaemia cells with an active PI3K/AKT pathway. Br J Haematol.
129:677–686. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chu ZH, Liang XH, Zhou XL, Huang RF, Zhan
Q and Jiang JW: Effects of deguelin on proliferation and apoptosis
of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt
signaling pathway. Zhong Xi Yi Jie He Xue Bao. 9:533–538. 2011.(In
Chinese).
|
|
14
|
Lee HY: Molecular mechanisms of
deguelin-induced apoptosis in transformed human bronchial
epithelial cells. Biochem Pharmacol. 68:1119–1124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li R, Chen Y, Shu WX, Chen Z and Ke WJ:
Involvement of SRC-3 in deguelin-induced apoptosis in Jurkat cells.
Int J Hematol. 89:628–635. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nair AS, Shishodia S, Ahn KS, Kunnumakkara
AB, Sethi G and Aggarwal BB: Deguelin, an Akt inhibitor, suppresses
IkappaBalpha kinase activation leading to suppression of
NF-kappaB-regulated gene expression, potentiation of apoptosis, and
inhibition of cellular invasion. J Immunol. 177:5612–5622. 2006.
View Article : Google Scholar
|
|
17
|
Dat NT, Lee JH, Lee K, Hong YS, Kim YH and
Lee JJ: Phenolic constituents of Amorpha fruticosa that
inhibit NF-kappaB activation and related gene expression. J Nat
Prod. 71:1696–1700. 2008.PubMed/NCBI
|
|
18
|
Geeraerts B, Vanhoecke B, Vanden Berghe W,
Philippe J, Offner F and Deforce D: Deguelin inhibits expression of
IkappaBalpha protein and induces apoptosis of B-CLL cells in vitro.
Leukemia. 21:1610–1618. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen WH, Chen Y and Cui GH: Deguelin
inhibits expression of IkappaBalpha protein in Raji and U937 cells.
Acta Pharmacol Sin. 27:485–490. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dell’Eva R, Ambrosini C, Minghelli S,
Noonan DM, Albini A and Ferrari N: The Akt inhibitor deguelin, is
an angiopreventive agent also acting on the NF-kappaB pathway.
Carcinogenesis. 28:404–413. 2007.PubMed/NCBI
|
|
21
|
Jin Q, Feng L, Behrens C, et al:
Implication of AMP-activated protein kinase and Akt-regulated
survivin in lung cancer chemopreventive activities of deguelin.
Cancer Res. 67:11630–11639. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiang X, Saha AK, Wen R, Ruderman NB and
Luo Z: AMP-activated protein kinase activators can inhibit the
growth of prostate cancer cells by multiple mechanisms. Biochem
Biophys Res Commun. 321:161–167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao C, Lu S, Kivlin R, et al:
AMP-activated protein kinase contributes to UV- and
H2O2-induced apoptosis in human skin
keratinocytes. J Biol Chem. 283:28897–28908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okoshi R, Ozaki T, Yamamoto H, et al:
Activation of AMP-activated protein kinase induces p53-dependent
apoptotic cell death in response to energetic stress. J Biol Chem.
283:3979–3987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng QY, Jin FS, Yao C, Zhang T, Zhang GH
and Ai X: Ursolic acid-induced AMP-activated protein kinase (AMPK)
activation contributes to growth inhibition and apoptosis in human
bladder cancer T24 cells. Biochem Biophys Res Commun. 419:741–747.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen MB, Shen WX, Yang Y, Wu XY, Gu JH and
Lu PH: Activation of AMP-activated protein kinase is involved in
vincristine-induced cell apoptosis in B16 melanoma cell. J Cell
Physiol. 226:1915–1925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murillo G, Salti GI, Kosmeder JW II,
Pezzuto JM and Mehta RG: Deguelin inhibits the growth of colon
cancer cells through the induction of apoptosis and cell cycle
arrest. Eur J Cancer. 38:2446–2454. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee HY, Suh YA, Kosmeder JW, Pezzuto JM,
Hong WK and Kurie JM: Deguelin-induced inhibition of
cyclooxygenase-2 expression in human bronchial epithelial cells.
Clin Cancer Res. 10:1074–1079. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murillo G, Peng X, Torres KE and Mehta RG:
Deguelin inhibits growth of breast cancer cells by modulating the
expression of key members of the Wnt signaling pathway. Cancer Prev
Res (Phila). 2:942–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu HL, Chen Y, Cui GH, Wu QL, Chen WH and
He J: Effect of deguelin on proliferation and apoptosis of lymphoma
Daudi cells and its mechanism. Zhonghua Zhong Liu Za Zhi.
29:176–180. 2007.(In Chinese).
|
|
31
|
Oh SH, Woo JK, Jin Q, et al:
Identification of novel antiangiogenic anticancer activities of
deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer.
122:5–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oh SH, Woo JK, Yazici YD, et al:
Structural basis for depletion of heat shock protein 90 client
proteins by deguelin. J Natl Cancer Inst. 99:949–961. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim WY, Oh SH, Woo JK, Hong WK and Lee HY:
Targeting heat shock protein 90 overrides the resistance of lung
cancer cells by blocking radiation-induced stabilization of
hypoxia-inducible factor-1alpha. Cancer Res. 69:1624–1632. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caboni P, Sherer TB, Zhang N, et al:
Rotenone, deguelin, their metabolites, and the rat model of
Parkinson’s disease. Chem Res Toxicol. 17:1540–1548.
2004.PubMed/NCBI
|
|
35
|
Kim WY, Chang DJ, Hennessy B, et al: A
novel derivative of the natural agent deguelin for cancer
chemoprevention and therapy. Cancer Prev Res (Phila). 1:577–587.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Greenamyre JT, Cannon JR, Drolet R and
Mastroberardino PG: Lessons from the rotenone model of Parkinson’s
disease. Trends Pharmacol Sci. 31:141–143. 2010.PubMed/NCBI
|
|
37
|
Banerji U, O’Donnell A, Scurr M, et al:
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,
17-demethoxygeldanamycin in patients with advanced malignancies. J
Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grem JL, Morrison G, Guo XD, et al: Phase
I and pharmacologic study of
17-(allylamino)-17-demethoxygeldanamycin in adult patients with
solid tumors. J Clin Oncol. 23:1885–1893. 2005. View Article : Google Scholar : PubMed/NCBI
|
